Scrambler Therapy in the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy

Exclusion Criteria

• •Any of the following: pregnant women, nursing women, women of childbearing potential or their sexual partners who are unwilling to employ adequate contraception (condoms, diaphragm, birth control pills, injections, intrauterine device \[IUD\], surgical sterilization, subcutaneous implants, abstinence, etc.).
• •Use of an investigational agent for pain control concurrently or within the past 30 days
• •History of an allergic reaction or previous intolerance to transcutaneous electronic nerve stimulation
• •Patients with implantable drug delivery systems, e.g. Medtronic Synchromed
• •Patients with heart stents or metal implants such as pacemakers, automatic defibrillators, cochlear implants, aneurysm clips, vena cava clips and skull plates. (Metal implants for orthopedic repair, e.g. pins, clips, plates, cages, joint replacements are allowed)
• •Patients with a history of myocardial infarction or ischemic heart disease within the past six months
• •Patients with history of epilepsy, brain damage, or symptomatic brain metastases
• •Prior celiac plexus block, or other neurolytic pain control treatment
• •Other identified causes of painful parasthesias existing prior to chemotherapy (e.g., radiation or malignant plexopathy, lumbar or cervical radiculopathy, pre-existing peripheral neuropathy of another etiology: e.g., carpal tunnel syndrome, B12 deficiency, AIDS, monoclonal gammopathy, diabetes, heavy metal poisoning amyloidosis, syphilis, hyperthyroidism or hypothyroidism, inherited neuropathy, etc.) that might be responsible for the patient's current neuropathic symptoms
• •Skin conditions such as open sores that would prevent proper application of the electrodes
• •Other medical or other condition(s) that in the opinion of the investigators might compromise the objectives of the study
• •Currently receiving anti-convulsants (such as gabapentinoids, e.g. gabapentin (Neurontin) or pregabalin (Lyrica). Because of data that support that patients do not do as well when on gabapentin or pregabalin, all patients on these medications will be weaned off them prior to study initiation. The study team will provide instructions on how to do this